“Our data suggest that microbiota-targeted interventions could mitigate the detrimental effects of early-life antibiotics on ...

Immunization programs save millions of lives every year by protecting against preventable diseases. The immune response to ...

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

Vaxcyte, Inc.'s positive phase 2 results for VAX-24 show promise in preventing invasive pneumococcal disease in infants.

The 13-valent pneumococcal conjugate vaccine (PCV13) has obtained the corresponding drug production license and has submitted a registration application to the National Medical Products Administration ...

The 13-valent pneumococcal conjugate vaccine (PCV13) has obtained the corresponding drug production license and has submitted ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

Capvaxive is a pneumococcal vaccine specifically designed to help protect adults ... for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate vaccine), as shown in these ...

“The happiness index changes after a certain age,” said secretary Arup Sinha. For seniors, wellness is about staying engaged ...

The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.